{"id":"acalabrutinib-monotherapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Bruising"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By selectively inhibiting BTK, acalabrutinib disrupts the B-cell receptor signaling pathway, leading to reduced survival and proliferation of malignant B cells, particularly in hematological cancers.","oneSentence":"Acalabrutinib inhibits Bruton's tyrosine kinase (BTK), which blocks B-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:32.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy"},{"name":"Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma"}]},"trialDetails":[{"nctId":"NCT07029737","phase":"PHASE2","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-05","conditions":"Mantle-cell Lymphoma","enrollment":55},{"nctId":"NCT06524375","phase":"PHASE2","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-08-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":118},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT04883437","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-09-03","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":49},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":310},{"nctId":"NCT07377578","phase":"PHASE3","title":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2026-02-05","conditions":"Mantle Cell Lymphoma","enrollment":394},{"nctId":"NCT06564038","phase":"PHASE1, PHASE2","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-01-30","conditions":"Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma","enrollment":276},{"nctId":"NCT04560322","phase":"PHASE2","title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-10-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT03328273","phase":"PHASE1","title":"A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2018-01-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT05645172","phase":"","title":"Retention Rate of Acalabrutinib in a Non-interventional Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-12","conditions":"Chronic Lymphocytic Leukaemia (CLL)","enrollment":137},{"nctId":"NCT06958705","phase":"PHASE2","title":"Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-01","conditions":"Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)","enrollment":79},{"nctId":"NCT06520098","phase":"PHASE2","title":"A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-10-01","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":100},{"nctId":"NCT02475681","phase":"PHASE3","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":535},{"nctId":"NCT03492125","phase":"PHASE1, PHASE2","title":"A Study Of The Selective PKC-β Inhibitor MS- 553","status":"TERMINATED","sponsor":"MingSight Pharmaceuticals, Inc","startDate":"2018-05-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma","enrollment":60},{"nctId":"NCT04630756","phase":"PHASE1, PHASE2","title":"AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-17","conditions":"Advanced Haematological Malignancies","enrollment":40},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT03685708","phase":"PHASE2","title":"HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Hepatitis, Safety and Tolerability","enrollment":78},{"nctId":"NCT02537444","phase":"PHASE2","title":"Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-11","conditions":"Ovarian Cancer","enrollment":78},{"nctId":"NCT02351739","phase":"PHASE2","title":"Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-04","conditions":"Metastatic Urothelial Carcinoma","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Maintenance Phase"],"phase":"phase_2","status":"active","brandName":"Acalabrutinib monotherapy","genericName":"Acalabrutinib monotherapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acalabrutinib inhibits Bruton's tyrosine kinase (BTK), which blocks B-cell activation and proliferation. Used for Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}